Revision of the American Joint Committee on Cancer Staging System for Breast Cancer

S. Eva Singletary(Memorial Sloan Kettering Cancer Center), Craig Allred(Memorial Sloan Kettering Cancer Center), Pandora Ashley(Memorial Sloan Kettering Cancer Center), Lawrence W. Bassett(Memorial Sloan Kettering Cancer Center), Donald A. Berry(Memorial Sloan Kettering Cancer Center), Kirby I. Bland(Memorial Sloan Kettering Cancer Center), Patrick I. Borgen(Memorial Sloan Kettering Cancer Center), Gary M. Clark(Memorial Sloan Kettering Cancer Center), Stephen B. Edge(Memorial Sloan Kettering Cancer Center), Daniel F. Hayes(Memorial Sloan Kettering Cancer Center), Lorie L. Hughes(Memorial Sloan Kettering Cancer Center), R. V. P. Hutter(Memorial Sloan Kettering Cancer Center), Monica Morrow(Memorial Sloan Kettering Cancer Center), David L. Page(Memorial Sloan Kettering Cancer Center), Abram Recht(Memorial Sloan Kettering Cancer Center), Richard L. Theriault(Memorial Sloan Kettering Cancer Center), Ann D. Thor(Memorial Sloan Kettering Cancer Center), Donald L. Weaver(Memorial Sloan Kettering Cancer Center), H. Samuel Wieand(Memorial Sloan Kettering Cancer Center), Frederick L. Greene(Memorial Sloan Kettering Cancer Center)
Journal of Clinical Oncology
August 29, 2002
Cited by 1,183

Abstract

PURPOSE: To revise the American Joint Committee on Cancer staging system for breast carcinoma. MATERIALS AND METHODS: A Breast Task Force submitted recommended changes and additions to the existing staging system that were (1) evidence-based and/or consistent with widespread clinical consensus about appropriate diagnostic and treatment standards and (2) useful for the uniform accrual of outcome information in national databases. RESULTS: Major changes included the following: size-based discrimination between micrometastases and isolated tumor cells; identifiers to indicate usage of innovative technical approaches; classification of lymph node status by number of involved axillary lymph nodes; and new classifications for metastasis to the infraclavicular, internal mammary, and supraclavicular lymph nodes. CONCLUSION: This revised staging system will be officially adopted for use in tumor registries in January 2003.


Related Papers

No related papers found

Powered by citation graph analysis